Although brain metastases occur in almost one-third of non-small cell lung cancer (NSCLC) patients, and immune checkpoint inhibitors (ICI) either as monotherapy or combined with chemotherapy are the new standard of care in the first line setting, most trials excluded patients with asymptomatic and/or untreated brain metastases. Brain metastases have a major clinical impact due to the worsening of the patient's prognosis and quality of life. Furthermore, the incidence of brain metastases is increasing in NSCLC patients, due to a longer survival and better imaging techniques. Therefore, brain metastases are increasingly becoming a research topic. Recent clinical data endorses ICI as a therapeutic strategy in this subpopulation of NSCLC patien...
Immune checkpoint inhibitors have revolutionized the treatment landscape for patients with non-small...
Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop brain metastases...
Brain metastases are frequent complications in patients with non-small-cell lung cancer (NSCLC) asso...
Although brain metastases occur in almost one-third of non-small cell lung cancer (NSCLC) patients, ...
Although brain metastases occur in almost one-third of non-small cell lung cancer (NSCLC) patients, ...
Although brain metastases occur in almost one-third of non-small cell lung cancer (NSCLC) patients, ...
Although brain metastases occur in almost one-third of non-small cell lung cancer (NSCLC) patients, ...
Although brain metastases occur in almost one-third of non-small cell lung cancer (NSCLC) patients, ...
Although brain metastases occur in almost one-third of non-small cell lung cancer (NSCLC) patients, ...
Abstract. Lung cancer has the highest risk of brain metastasis (BM) among all solid carcinomas. The ...
Brain metastases (BM) are diagnosed frequently in non-small cell lung cancer (NSCLC) patients. Despi...
Brain metastases (BM) are diagnosed frequently in non-small cell lung cancer (NSCLC) patients. Despi...
Brain metastases (BM) are diagnosed frequently in non-small cell lung cancer (NSCLC) patients. Despi...
Brain metastases (BM) are diagnosed frequently in non-small cell lung cancer (NSCLC) patients. Despi...
Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop brain metastases...
Immune checkpoint inhibitors have revolutionized the treatment landscape for patients with non-small...
Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop brain metastases...
Brain metastases are frequent complications in patients with non-small-cell lung cancer (NSCLC) asso...
Although brain metastases occur in almost one-third of non-small cell lung cancer (NSCLC) patients, ...
Although brain metastases occur in almost one-third of non-small cell lung cancer (NSCLC) patients, ...
Although brain metastases occur in almost one-third of non-small cell lung cancer (NSCLC) patients, ...
Although brain metastases occur in almost one-third of non-small cell lung cancer (NSCLC) patients, ...
Although brain metastases occur in almost one-third of non-small cell lung cancer (NSCLC) patients, ...
Although brain metastases occur in almost one-third of non-small cell lung cancer (NSCLC) patients, ...
Abstract. Lung cancer has the highest risk of brain metastasis (BM) among all solid carcinomas. The ...
Brain metastases (BM) are diagnosed frequently in non-small cell lung cancer (NSCLC) patients. Despi...
Brain metastases (BM) are diagnosed frequently in non-small cell lung cancer (NSCLC) patients. Despi...
Brain metastases (BM) are diagnosed frequently in non-small cell lung cancer (NSCLC) patients. Despi...
Brain metastases (BM) are diagnosed frequently in non-small cell lung cancer (NSCLC) patients. Despi...
Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop brain metastases...
Immune checkpoint inhibitors have revolutionized the treatment landscape for patients with non-small...
Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop brain metastases...
Brain metastases are frequent complications in patients with non-small-cell lung cancer (NSCLC) asso...